Pharma Deals Review, Vol 2013, No 7 (2013)

Font Size:  Small  Medium  Large

AstraZeneca Strengthens Core Respiratory Business with US$1.15 B Pearl Therapeutics Purchase

Heather Cartwright

Abstract


In a move that provides a much-needed boost to the company’s beleaguered late-stage pipeline, AstraZeneca has agreed to acquire Pearl Therapeutics, a US-based developer of combination therapies for chronic respiratory diseases, in a deal worth up to US$1.15 B. Respiratory, inflammation and autoimmunity represents one of three core therapeutic areas of focus for AstraZeneca as part of its new growth strategy. With the acquisition, the company will gain PT003, a fixed-dose combination of formoterol fumarate and glycopyrrolate that is in Phase III development for moderate-to-severe chronic obstructive pulmonary disease (COPD).



Add comment

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.